Jay Moorin, Partner
 

Mr. Moorin has been a managing member of the General Partner and of ProQuest since its founding in 1998. He is a seasoned healthcare executive whose background includes senior roles in leading investment banking, pharmaceutical and biotech companies. Mr. Moorin led ProQuest's investments in U.S. Bioscience, Epic Therapeutics, and Pharmion, among others. He currently serves on the Board of Directors of ACMI, Acurian, Gloucester Pharmaceuticals, Guava Technologies, and Novacea.

Prior to joining ProQuest, Mr. Moorin served as Chairman, President and Chief Executive Officer of Magainin Pharmaceuticals, Inc. (now Genaera Corp.), a venture-backed biotechnology company developing novel antibiotics and oncology drugs. During his tenure at Magainin, Mr. Moorin raised over $150 million in private and public capital, oversaw the development of a new technology from initial discovery through clinical research to a New Drug Application with the FDA, and forged collaborations with leading pharmaceutical companies such as SmithKline Beecham and Sandoz (now Novartis). Previously, as Managing Director, Health Care Banking at Bear, Stearns & Co., Inc., he was involved in a number of innovative transactions, including managing one of the first biotech mergers, privatizing a specialty pharmaceutical firm, and closing one of the first PIPE financings for a biotech company. In 1983, he joined E.R. Squibb and Sons Pharmaceuticals, Inc., where he held positions in marketing, strategy and general management, ultimately becoming the youngest vice president in the corporation at that time, serving as Vice President of Marketing & Business Development in the SquibbMark Division.

In 1996, Mr. Moorin was appointed to the position of Adjunct Senior Fellow of the Leonard Davis Institute of Health Economics at the University of Pennsylvania. He holds a B.A. with distinction in economics from the University of Michigan.